Skip to main content

Table 1 Categorisation 1: non-high FeNO and non-high blood eosinophils vs. high FeNO and high blood eosinophils

From: Association of elevated fractional exhaled nitric oxide concentration and blood eosinophil count with severe asthma exacerbations

Characteristics Non-high FeNO and non-high blood eosinophils (n = 27) High FeNO and high blood eosinophils (n = 27) p-value
Sex
 n (% non-missing) 27 (100.0) 27 (100.0) 1.0000
 Male 10 (37.0) 10 (37.0)  
Age
 n (% non-missing) 27 (100.0) 27 (100.0) 0.9379
 Mean (SD) 43.5 (18.8) 43.3 (19.0)  
 Median (IQR) 41.0 (37.0) 41.0 (37.0)  
Age group
 n (% non-missing) 27 (100.0) 27 (100.0) 1.0000
 Under 35 12 (44.4) 12 (44.4)  
 35–65 9 (33.3) 9 (33.3)  
 66–80 6 (22.2) 6 (22.2)  
Smoking status
 n (% non-missing) 27 (100.0) 27 (100.0) 0.7645
 Non-smoker 13 (48.1) 14 (51.9)  
 Ex-smoker 1 (3.7) 2 (7.4)  
 Current smoker 13 (48.1) 11 (40.7)  
BMI    
 n (% non-missing) 23 (85.2) 26 (96.3) 0.4346
 Mean (SD) 27.7 (7.2) 26.9 (6.4)  
 Median (IQR) 26.8 (5.5) 25.5 (8.4)  
Active eczema diagnosisa
 n (% non-missing) 27 (100.0) 27 (100.0) 0.6387
 Yes 3 (11.1) 2 (7.4)  
Active rhinitis diagnosisa
 n (% non-missing) 27 (100.0) 27 (100.0) 0.2482
 Yes 7 (25.9) 11 (40.7)  
Eczema diagnosis
 n (% non-missing) 27 (100.0) 27 (100.0) 0.7801
 Yes 10 (37.0) 11 (40.7)  
Rhinitis diagnosis
 n (% non-missing) 27 (100.0) 27 (100.0) 0.1628
 Yes 8 (29.6) 13 (48.1)  
IHD diagnosis
 n (% non-missing) 27 (100.0) 27 (100.0) 0.5525
 Yes 2 (7.4) 1 (3.7)  
Heart failure diagnosis
 n (% non-missing) 27 (100.0) 27 (100.0)  
 Yes 0 (0.0) 0 (0.0)  
Hypertension diagnosis
 n (% non-missing) 27 (100.0) 27 (100.0) 0.4436
 Yes 5 (18.5) 3 (11.1)  
Diabetes diagnosis
 n (% non-missing) 27 (100.0) 27 (100.0)  
 Yes 0 (0.0) 0 (0.0)  
GERD active diagnosis
 n (% non-missing) 27 (100.0) 27 (100.0) 0.3128
 Yes 1 (3.7) 0 (0.0)  
Predicted peak flow
 n (% non-missing) 14 (51.9) 20 (74.1) 0.9721
 Mean (SD) 488.9 (53.4) 505.8 (74.9)  
 Median (IQR) 482.7 (47.2) 478.3 (127.7)  
ICS/LABA prescriptions per patient
 n (% non-missing) 27 (100.0) 27 (100.0) 0.6546
 Mean (SD) 3.6 (4.3) 3.2 (2.5)  
 Median (IQR) 1.0 (7.0) 3.0 (5.0)  
Mono ICS prescriptions per patient
 n (% non-missing) 27 (100.0) 27 (100.0) 0.4898
 Mean (SD) 1.2 (1.9) 1.0 (2.2)  
 Median (IQR) 0.0 (2.0) 0.0 (1.0)  
Mean daily SABA dosage (µg)
 n (% non-missing) 27 (100.0) 27 (100.0) 0.5066
 < 100 8 (29.6) 6 (22.2)  
 100–200 11 (40.7) 8 (29.6)  
 201–400 6 (22.2) 8 (29.6)  
 > 400 2 (7.4) 5 (18.5)  
ICS adherenceb
 n (% non-missing) 27 (100.0) 27 (100.0) 0.7158
 Mean (SD) 57.1 (39.3) 52.3 (32.9)  
 Median (IQR) 54.8 (54.8) 49.3 (35.7)  
  1. All values in the table are n (%) unless otherwise specified. High FeNO defined as ≥ 50 ppb; non-high FeNO < 25 ppb; high blood eosinophil count defined as ≥ 0.300 × 109 cells/L; non-high blood eosinophil count < 0.300 × 109 cells/L
  2. ATS American Thoracic Society, BMI body mass index, FeNO fractional exhaled nitric oxide, GERD gastroesophageal reflux disease, ICS inhaled corticosteroid, IHD ischaemic heart disease, IQR interquartile range, LABA long-acting β2-agonist, ppb parts per billion, SABA short-acting β2-agonist, SD standard deviation
  3. aActive denotes diagnosed in the year before FeNO reading or treated in the year before FeNO reading
  4. bMedication Possession Ratio was calculated by dividing the total of 1 day’s supply by the total number of days evaluated, multiplied by 100%. The evaluation period for all patients was 365 days in the study year